ECTRIMS: New Biologic Drug Shows Promise in MS MedPage Today Explain that treatment with daclizumab (Zenapax), an investigational monoclonal antibody drug, cut annualized relapse rates in half among patients with early relapsing-remitting multiple sclerosis (MS) in a placebo-controlled trial. ... |
